TY - JOUR
T1 - Intravitreal bevacizumab treatment for neovascular glaucoma
T2 - Histopathological analysis of trabeculectomy specimens
AU - Yoshida, Noriko
AU - Hisatomi, Toshio
AU - Ikeda, Yasuhiro
AU - Kohno, Ri Ichiro
AU - Murakami, Yusuke
AU - Imaki, Hiroyuki
AU - Ueno, Akifumi
AU - Fujisawa, Kimihiko
AU - Ishibashi, Tatsuro
N1 - Funding Information:
Acknowledgements We thank Y. Morikawa and M. Imamura for assistance with the experiments. KN International provided language assistance. This work was supported in part by a Grant-in-Aid (to YI) from the Japanese Ministry of Education, Culture, Sports, Science, and Technology (#20791259).
PY - 2011/10
Y1 - 2011/10
N2 - Background: Neovascular glaucoma (NVG) is a serious complication for patients with proliferative diabetic retinopathy (PDR). Bevacizumab is a full-length humanized monoclonal antibody that binds all isoforms of vascular endothelial growth factor (VEGF). Recently, encouraging results regarding the off-label use of intravitreal bevacizumab (IVB) for the treatment of NVG have been reported. We evaluated the histology of bevacizumab-treated trabeculectomy specimens to clarify IVB's biological effects on angle neovascularization. Methods: We retrospectively reviewed the charts of a consecutive series of 15 eyes of 13 patients who underwent trabeculectomy to treat NVG caused by PDR. In ten eyes of eight patients, 1.25 mg bevacizumab was injected intravitreally via the pars plana. Using light or electron microscopy, the surgically excised trabecular tissue was compared to that without IVB. Results: Light microscopy revealed decreased edema, fibrin deposition, inflammation and vascular congestion in the trabecular meshwork in specimens with IVB compared to those without IVB. Electron microscopy revealed endothelial cell degeneration in the bevacizumab-treated specimens. Conclusions: The biological effects on angle neovascularization after IVB may involve reduced vascular permeability, decreased inflammatory reaction, loss of vascular function, and endothelial cell degeneration.
AB - Background: Neovascular glaucoma (NVG) is a serious complication for patients with proliferative diabetic retinopathy (PDR). Bevacizumab is a full-length humanized monoclonal antibody that binds all isoforms of vascular endothelial growth factor (VEGF). Recently, encouraging results regarding the off-label use of intravitreal bevacizumab (IVB) for the treatment of NVG have been reported. We evaluated the histology of bevacizumab-treated trabeculectomy specimens to clarify IVB's biological effects on angle neovascularization. Methods: We retrospectively reviewed the charts of a consecutive series of 15 eyes of 13 patients who underwent trabeculectomy to treat NVG caused by PDR. In ten eyes of eight patients, 1.25 mg bevacizumab was injected intravitreally via the pars plana. Using light or electron microscopy, the surgically excised trabecular tissue was compared to that without IVB. Results: Light microscopy revealed decreased edema, fibrin deposition, inflammation and vascular congestion in the trabecular meshwork in specimens with IVB compared to those without IVB. Electron microscopy revealed endothelial cell degeneration in the bevacizumab-treated specimens. Conclusions: The biological effects on angle neovascularization after IVB may involve reduced vascular permeability, decreased inflammatory reaction, loss of vascular function, and endothelial cell degeneration.
UR - http://www.scopus.com/inward/record.url?scp=80755155795&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80755155795&partnerID=8YFLogxK
U2 - 10.1007/s00417-011-1761-2
DO - 10.1007/s00417-011-1761-2
M3 - Article
C2 - 21842129
AN - SCOPUS:80755155795
SN - 0065-6100
VL - 249
SP - 1547
EP - 1552
JO - Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie
JF - Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie
IS - 10
ER -
